血小板糖蛋白Ib拮抗剂anfibatide在血栓性血小板减少性紫癜小鼠模型中的治疗疗效
本研究在自发血小板减少和志贺毒素诱导的血栓性血小板减少性紫癜(TTP)小鼠模型中评估蛇毒来源血小板糖蛋白Ib拮抗剂anfibatide的疗效。结果显示anfibatide呈浓度依赖性抑制冯·维勒布兰德因子存在下的血小板凝集,并抑制动脉剪切应力下血小板黏附与聚集;腹腔注射60 ng/g体重每日两次可减轻Adamts13-/-及CAST/Ei小鼠的自发性血小板减少并预防志贺毒素诱导的TTP。
要点
- anfibatide呈浓度依赖性抑制瑞斯托霉素或博托霉素诱导的人或小鼠血小板凝集。
- anfibatide抑制动脉剪切应力下小鼠及人血小板在胶原表面的黏附和聚集。
- 腹腔注射60 ng/g体重每日两次可减轻小鼠自发性血小板减少并预防志贺毒素诱导的TTP。
核心结论
- anfibatide在最佳剂量、途径和间隔下对小鼠模型中的自发性和细菌志贺毒素诱导的TTP有效。
- 研究结果为进一步开发anfibatide用于治疗人类急性TTP提供了基础。
研究设计与样本
- 研究采用光散射血小板聚集测定、基于微流控剪切力的实验和TTP小鼠模型。
- 在Adamts13-/-小鼠和疾病易感小鼠(CAST/Ei株)中评估anfibatide的疗效。
主要发现
- 纯化anfibatide在冯·维勒布兰德因子存在下呈浓度依赖性抑制瑞斯托霉素或博托霉素诱导的人或小鼠血小板凝集。
- anfibatide在有无血浆ADAMTS13活性时均能显著抑制动脉剪切应力下小鼠和人血小板在胶原表面的黏附和聚集。
- 腹腔注射anfibatide 60 ng/g体重每日两次减轻了Adamts13-/-和疾病易感小鼠(CAST/Ei株)的自发性血小板减少。
- 腹腔注射anfibatide 60 ng/g体重每日两次预防了Adamts13-/-和疾病易感小鼠(CAST/Ei株)的志贺毒素诱导的TTP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombotic thrombocytopenic purpura (TTP), a potentially fatal blood clot disorder, is primarily caused by severe deficiency of plasma ADAMTS13 activity resulting from acquired autoantibodies. Plasma exchange is the only effective initial therapy. However, the high mortality rate and the complications associated with plasma exchange therapy remain a major concern. To address unmet clinical needs, therapeutic efficacies of anfibatide, a snake venom-derived platelet glycoprotein Ib antagonist, in murine models of spontaneous thrombocytopenia and shigatoxin-induced TTP were determined. A light scattering platelet aggregometry, microfluidic shear-based assay, and murine models of TTP were used in the study. We showed that purified anfibatide inhibits ristocetin- or botrocetin-induced human or murine platelet agglutination in the presence of von Willebrand factor in a concentration-dependent manner. Anfibatide could also dramatically inhibit the adhesion and aggregation of murine and human platelets on a collagen surface under arterial shear stress, in the presence or absence of plasma ADAMTS13 activity. Most importantly, we demonstrated that an intraperitoneal administration of anfibatide at the dose of 60 ng/g body weight twice daily mitigated spontaneous thrombocytopenia and prevented shigatoxin-induced TTP in Adamts13-/- and disease-susceptible mice (CAST/Ei strain). Thus, we conclude that anfibatide, when administered at the optimal dosage, route, and interval, is efficacious in treating spontaneous and bacterial shigatoxin-induced TTP in the murine models. Our findings may provide the basis for further development of anfibatide for the treatment of acute TTP in humans.
引用
- Zheng L, Mao Y, Abdelgawwad MS, et al. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. Blood Adv. 2016. PMID: 28480350. doi:10.1182/bloodadvances.2016000711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。